Chlamydial pathogenesis: Diagnostic and therapeutic consequences;Histoire naturelle des infections à Chlamydiaphysiopathologie des infections à Chlamydia: Conséquences diagnostiques et thérapeutiques

Archives de Pediatrie

Volumn 12, Issue SUPPL. 1, 2005, Pages

  De Barbeyrac, B ^a   Bebear C ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chlamydia infections

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL ANTIGEN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; SPARFLOXACIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CORONARY ARTERY DISEASE; HUMAN; INFERTILITY; INFLAMMATION; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PERSISTENT INFECTION; TREATMENT FAILURE;

EID: 18844444540     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(05)80007-7     Document Type: Article

References (12)

1. Moulder J.W., Levy N.J., and Schulman L.P. Persistent infection of mouse fibroblasts (L cells) with Chlamydia psittaci: evidence for a cryptic chlamydial form Infect Immun 30 1980 874 883
2. Hogan R.J., Mathews S.A., Mukhopadhyay S., Summersgill J.T., and Timms P. Chlamydial persistence: beyond the biphasic paradigm Infect Immun 72 2004 1843 1855
3. Stephens R.S. The cellular paradigm of chlamydial pathogenesis Trends Microbiol 11 2003 44 51
4. Belland R.J., Ouellette S.P., Gieffers J., and Byrne G.I. Chlamydia pneumoniae and atherosclerosis Cellular Microbiology 6 2004 117 127
5. Campbell L.A., and Kuo C.C. Chlamydia pneumoniae -- An infectious risk factor for atherosclerosis? Nature Reviews Microbiology 2 2004 23 32
6. Witkin S.S. Immunological aspects of genital chlamydia infections Best Practice and Research in Clinical Obstetrics and Gynaecology 16 2002 865 874
7. Anderson J.L., and Muhlestein J.B. Antibiotic trials for coronary heart disease Texas Heart Institute Journal 31 1 2004 33 38
8. Kelly K.A. Cellular immunity and Chlamydia genital infection: Induction, recruitment, and effectors mechanisms International Reviews of Immunology 22 2003 3 41
9. Morre S.A., Murillo L.S., Bruggeman C.A., and Pena A.S. The role that the functional Asp299Gly polymorphism in the toll-like receptor-4 gene plays in susceptibility to Chlamydia trachomatis-associated tubal infertility Journal of Infectious Diseases 187 2003 341 342
10. Barbeyrac Bd. Les chlamydiae: épidémiologie -- diagnostic biologique Bébéar C. Mycoplasmes et Chlamydiae 2002 Elsevier Paris 49 68
11. Dessus-Babus S., Bebear C.M., Charron A., Bebear C., and De Barbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistancedetermining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro Antimicrob Agents Chemother 42 1998 2474 2481
12. Kodaman P.H., Arici A., and Seli E. Evidence-based diagnosis and management of tubal factor infertility Current Opinion in Obstetrics and Gynecology 16 2004 221 229